Redeye comments on Episurf’s rights issue of Units, which was oversubscribed to approximately 162.
We hosted NoHo Partners' CEO Jarno Suominen for a lunch meeting today in Helsinki.
Redeye provides its preview of Integrum’s Q1 2025 report, due on Monday, September 1.
Nettoomsättningen för det andra kvartalet uppgick till 6,6 MEURO (10,2), vilket motsvarade en minskn...
Redeye reviews the case for IDL Diagnostics, and while we down our medium-term sales forecasts, we r...
Redeye views InfraCom’s Q2 2025 results as mixed, with a declining top line contrasted by rising EBI...
Crunchfish’s new go-to-market strategy for offline payments, splitting the solution into terminals f...
Cantargia’s Q2 report covers one of the most eventful periods in the company’s history.
Redeye provides an update following CLS’s Q2 2025 report.
Redeye argues that AVTECH has delivered another strong report with sales growth of 37% y/y, which wa...
Redeye lowers its estimates on the back of I-Tech’s second quarter, which showed a surprising slowdo...
* A quarter centred on preparations * Orviglance FDA submission around the corner * Fair value range...
Redeye provides an in-depth review of Acarix’s Q2 report and related events during and after the qua...
* Gross margin at 45% (40%) * SaaS supports margins and outlook * Trading at ~11-9x EV/EBITA for '26...
* Q2 sales +3% and EBITDA +4% vs. ABGSCe * We raise EBITDA by 1-4% and EBIT by 4-8% for '26e-'27e * ...
Acuvi redovisade ökad nettoomsättning och EBIT i det andra kvartalet.
Redeye provides a research update following the Q2 report recently published by Initiator Pharma.
* Sales SEK 6.5m, EBIT SEK -16m (vs. ABGSCe 11m and -12m) * No machine deliveries in the quarter (in...
